• Vaccine Name: SAd-ME.TRAP
• Target Pathogen: malaria
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• Vector:
  • Vector name:
  • VO vector ID: VO_0001047
• Preparation: Three chimpanzee-origin adenoviral vectors, AdC6, AdC7 and AdC9 containing ME.TRAP as an insert (Reyes-Sandoval et al., 2008).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Vaccination Protocol: Mice were immunized with adenoviral (1 × 10^10 vp) and poxviral vectors (1 × 10^7 PFU) (Reyes-Sandoval et al., 2008).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: Mice were challenged 14 days and 60 days post immunization by i.v. administration of 1000 sporozoites of Plasmodium berghei (Reyes-Sandoval et al., 2008).
• Efficacy: Protection was afforded by the SAd despite high levels of pre-existing immunity to AdH5. Phenotypic analysis showed that all adenoviral vectors (Ad) elicited CD8(+) T cell responses with an effector memory T cell (T(EM)) phenotype. By contrast, vaccination with poxviral vectors did not confer protection to P. berghei and induced a predominantly CD8(+) central memory T cell (T(CM)) response. Multifunctional CD8(+) T cell responses (co-expressing IFN-gamma, TNF-alpha and IL-2) were also induced by the Ad in higher percentages than the poxviral vectors (Reyes-Sandoval et al., 2008).